CIK 0001175151
- Non-accelerated filer
- Smaller reporting company
Cytosorbents Corp
Sign in to watch- Ticker
- CTSO
- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 980373793
- Phone
- +1 973-329-8885
- Business address
- 305 COLLEGE ROAD EAST, PRINCETON, NJ, 08540
- Former names
- MedaSorb Technologies CORP, GILDER ENTERPRISES INC
- Open-market buys, last 90 days
- $120,435
- in 4 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$120,435. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-08-08 | Deliargyris Efthymios Chief Medical Officer | Grant or award | +70,000 | 473,025 | ||
| 2025-08-08 | Deliargyris Efthymios Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +95,000 | 95,000 | ||
| 2025-01-17 | Deliargyris Efthymios Chief Medical Officer | Option exercise | +16,233 | $1.00 | $16K | 403,025 |
| 2025-01-17 | Deliargyris Efthymios Chief Medical Officer | Option exercise · Subscription Rights (right to buy) | −16,233 | 0 | ||
| 2025-01-17 | Deliargyris Efthymios Chief Medical Officer | Other acquisition · Series A Right Warrants | +16,233 | 16,233 | ||
| 2025-01-17 | Deliargyris Efthymios Chief Medical Officer | Other acquisition · Series B Right Warrants | +16,233 | 16,233 | ||
| 2024-10-04 | Deliargyris Efthymios Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2024-10-04 | Deliargyris Efthymios Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2024-04-02 | Deliargyris Efthymios Chief Medical Officer | Grant or award | +61,000 | 409,433 | ||
| 2024-04-02 | Deliargyris Efthymios Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +86,000 | 86,000 | ||
| 2024-03-29 | Deliargyris Efthymios Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +47,088 | 47,088 | ||
| 2023-12-13 | Deliargyris Efthymios Chief Medical Officer | Purchase | +22,557 | $1.33 | $30K | 348,433 |
| 2023-12-13 | Deliargyris Efthymios Chief Medical Officer | Purchase · Common Stock Warrant (Right to Buy) | +7,894 | 7,894 | ||
| 2023-07-07 | Deliargyris Efthymios Chief Medical Officer | Grant or award | +55,000 | 331,648 | ||
| 2023-07-07 | Deliargyris Efthymios Chief Medical Officer | Grant or award · Stock Option (right to buy) | +78,000 | 78,000 | ||
| 2023-07-07 | Deliargyris Efthymios Chief Medical Officer | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2022-08-10 | Deliargyris Efthymios Chief Medical Officer | Grant or award | +55,000 | 228,384 | ||
| 2022-08-10 | Deliargyris Efthymios Chief Medical Officer | Grant or award | +52,000 | 283,384 | ||
| 2022-08-10 | Deliargyris Efthymios Chief Medical Officer | Grant or award · Stock Option (right to buy) | +74,000 | 74,000 | ||
| 2022-08-10 | Deliargyris Efthymios Chief Medical Officer | Grant or award · Stock Option (right to buy) | +300,000 | 300,000 |
Page 1 of 2 · 24 trades